Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations analyze found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which re